---
title: "16:44 ET/C O R R E C T I O N -- Skyhawk Therapeutics/"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286817312.md"
description: "Dragonfly Therapeutics announced encouraging early results from its Phase 1 trial for DF5112, a CCR6-targeting molecule. The trial has successfully dosed healthy volunteers subcutaneously after completing intravenous dosing, showing strong depletion of Th17 and B cells. CEO Bill Haney expressed enthusiasm for the program's potential in treating autoimmune diseases. The Phase 1 trial aims to evaluate safety, tolerability, and pharmacodynamics of DF5112."
datetime: "2026-05-18T20:45:40.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286817312.md)
  - [en](https://longbridge.com/en/news/286817312.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286817312.md)
---

# 16:44 ET/C O R R E C T I O N -- Skyhawk Therapeutics/

In the news release, Dragonfly Therapeutics Announces Encouraging Early Results from the Phase 1 for DF5112, its CCR6-Targeting Molecule, issued 18-May-2026 by Skyhawk Therapeutics over PR Newswire, we are advised by the company that changes have been made. The complete, corrected release follows:

### Dragonfly Therapeutics Announces Encouraging Early Results from the Phase 1 for DF5112, its CCR6-Targeting Molecule

_DF5112 provides deep Th17 and B cell depletion in IV cohort and is now dosing its Phase 1 subcutaneous cohorts._

, /PRNewswire/ -- Dragonfly Therapeutics, a clinical-stage biopharmaceutical company pioneering novel immunotherapies, today announced that the first healthy volunteers have been successfully dosed subcutaneously (SC) with its CCR6-targeting molecule, DF5112. This milestone follows the successful completion of the intravenous (IV) dosing phase which demonstrated DF5112's strong depletion of both Th17 and B cells.

By targeting CCR6 to therapeutically deplete both Th17 cells and B cells — two key immune cell populations implicated in a range of autoimmune and inflammatory diseases — DF5112 offers the potential for distinctively appealing immunomodulatory activity.

_"We are enthusiastic about the early results from our CCR6 program," said Bill Haney, Dragonfly's CEO. "We are excited to be advancing DF5112 for patients suffering from autoimmune diseases ranging from psoriatic arthritis and Sjögren's, to systemic sclerosis and hidradenitis suppurativa."_

**About DF5112's Phase 1 Trial  
**DF5112's Phase 1 (NCT07232121) is a double-blind, randomized, placebo-controlled study to evaluate safety, tolerability, pharmacokinetics, immunogenicity and pharmacodynamics of DF5112 in healthy adult participants.

**About Dragonfly Therapeutics  
**Dragonfly is a clinical-stage biopharmaceutical company developing advanced immunotherapies for vastly improved patient outcomes. The company's pipeline includes programs targeting autoimmune disease, oncology, fibrosis, and neuroinflammatory conditions, leveraging its proprietary platform and other modalities.

Dragonfly is a subsidiary of Skyhawk Therapeutics.

**Media Contact:  
**Maura McCarthy  
Dragonfly Therapeutics  
\[email protected\]

**Correction:** In the first paragraph, "patients" has been changed to "healthy volunteers."

SOURCE Skyhawk Therapeutics

## Related News & Research

- [08:10 ETCelltaxis Names Co-Founder Eileen Heffernan as CEO to Accelerate Growth and Expand Leadership in Lymphatic Disease Therapeutics](https://longbridge.com/en/news/289781004.md)
- [15:49 ETBreakthrough T1D Presents New Jersey Resident Gina Gehan with the 2025 Huntsman Family Community Engagement Award](https://longbridge.com/en/news/289822007.md)
- [15:58 ETC-Path Reaffirms Commitment to Advancing Regulatory Science for Disease-Modifying Therapies in Type 1 Diabetes](https://longbridge.com/en/news/289822288.md)
- [REG - CRISM Therapeutics - Result of General Meeting](https://longbridge.com/en/news/289765862.md)
- [CONNECTA Therapeutics begins Phase IIa trial of CTH120 for FXS](https://longbridge.com/en/news/289437178.md)